Passage BIO Inc
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
PASG$3.43-13.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three Months Ended | ||||||
| · · March 31, | ||||||
| (in thousands) · 2025 · 2024 | ||||||
| Cash flows used in operating activities: · · | ||||||
| Net loss | | $(15,405) | | $(16,711) | ||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | | | | |||
| Depreciation and amortization | | 201 | | 806 | ||
| Share‑based compensation | | 858 | | 1,595 | ||
| Amortization of premium and discount on marketable securities, net | | | 129 | | | (444) |
| Impairment of long-lived assets | | | 2,637 | | — | |
| Changes in operating assets and liabilities: | | | | |||
| Prepaid expenses and other current assets, and other assets | | (709) | | (1,090) | ||
| Prepaid research and development | | 30 | | 758 | ||
| Non-refundable sublicense and transition services payments received | | | 506 | | | — |
| Right of use assets and operating lease liabilities | | | (97) | | | (45) |
| Accounts payable | | 716 | | 389 | ||
| Accrued expenses and other current liabilities | | (2,713) | | (4,187) | ||
| Net cash provided by (used in) operating activities | | (13,847) | | (18,929) | ||
| Cash flows provided by (used in) investing activities: | | | ||||
| Purchases of marketable securities | | — | | (13,809) | ||
| Sales or maturities of marketable securities | | 39,046 | | 39,060 | ||
| Sale of property and equipment and other assets | | 585 | | — | ||
| Net cash provided by (used in) investing activities | | 39,631 | | 25,251 | ||
| Cash flows provided by (used in) financing activities: | | | ||||
| Proceeds from issuance of common stock under the ATM Facility, net of offering costs | | | — | | | 8,742 |
| Net cash provided by (used in) financing activities | | — | | 8,742 | ||
| Net increase (decrease) in cash and cash equivalents | | 25,784 | | 15,064 | ||
| Cash and cash equivalents at beginning of period | | 37,573 | | 21,709 | ||
| Cash and cash equivalents at end of period | | $63,357 | | $36,773 | ||
| Supplemental disclosure of non‑cash investing and financing activities: | | | | |||
| Unrealized gain (loss) on marketable securities | | $(8) | | $(26) | ||
| Deferred proceeds from equipment sale in other current assets | | | (585) | | | — |
| Right of use assets recognized upon the commencement of sublease | | $— | | $(422) | ||
| Operating lease liabilities recognized upon the commencement of sublease | | $— | | $422 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.